Author:
Kadeetham Khunthorn,Samankatiwat Piya
Abstract
Abstract
Objectives
Since the introduction of surgical implantation of conduit for right ventricle-to-pulmonary artery pathway reconstruction, there has been a number of studies on possible factors which might potentially affect conduit longevity, as well as patient’s reintervention-free and overall survival. Still, no definite consensual agreement could be made thus far. We aimed to compare conduit longevity, reintervention-free survival, and overall survival between patients with congenital heart diseases indicated for operations involving right ventricle-to-pulmonary artery pathway reconstruction whose conduits were placed heterotopically to those with orthotopically placed ones.
Materials and methods
We retrospectively collected data from electronic medical records of Ramathibodi hospital from 1st January 2005 to 31st December 2022. Patients with congenital heart diseases whose operations involved reconstruction of right ventricle-to-pulmonary artery continuity were included. Patients whose medical record data were significantly missing were excluded. Demographic data, operative, and postoperative details were collected and reviewed.
Results
There were 67 patients included in our study, with 25 receiving orthotopic and the other 42 receiving heterotopic conduit implantation. Conduit dysfunction-free, reintervention-free, and overall survival were not statistically different between both groups. There was 1 early and no late death up to the end date of our study.
Conclusions
Conduits placed on a heterotopic position did not result in worse longevity, reintervention-free survival, as well as overall survival when compared to conduits placed on an orthotopic position. This suggested that the less technically demanding heterotopic conduit placement could be recommended as an operation of choice for right ventricular outflow tract reconstruction.
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,General Medicine,Surgery,Pulmonary and Respiratory Medicine
Reference30 articles.
1. Ross DN, Somerville J. Correction of pulmonary atresia with a homograft aortic valve. Lancet. 1966;2(7479):1446–7.
2. Rastelli GC, Ongley PA, Davis GD, Kirklin JW. Surgical repair for pulmonary valve atresia with coronary-pulmonary artery fistula: report of case. Mayo Clin Proc. 1965;40:521–7.
3. Ruzmetov M, Geiss DM, Shah JJ, Fortuna RS, Welke KF. Does the homograft for RVOT reconstruction in ross: patients fare better than for non-Ross patients? A single-center experience. J Heart Valve Dis. 2015;24(4):478–83.
4. Selamet Tierney ES, Gersony WM, Altmann K, Solowiejczyk DE, Bevilacqua LM, Khan C, Krongrad E, Mosca RS, Quaegebeur JM, Apfel HD. Pulmonary position cryopreserved homografts: durability in pediatric Ross and non-Ross patients. J Thorac Cardiovasc Surg. 2005;130(2):282–6.
5. Pearl JM, Laks H, Drinkwater DC Jr, Loo DK, George BL, Williams RG. Repair of conotruncal abnormalities with the use of the valved conduit: improved early and midterm results with the cryopreserved homograft. J Am Coll Cardiol. 1992;20(1):191–6.